Davies Sally C, Oxlade Claire
Department of Health and Social Care London, UK.
Department of Health and Social Care, London, UK.
Future Healthc J. 2021 Jul;8(2):e251-e256. doi: 10.7861/fhj.2021-0087.
As drug-resistant pathogens emerge and spread globally, antimicrobial (especially antibiotic) treatments are becoming less effective. As infections become more complex and costly to treat in humans and animals, antimicrobial resistance (AMR) is a global challenge of real and increasing scale and complexity. If we do not act for the long term and with sustainability in mind, the annual deaths we see currently, numbering 700,000 globally, will rise each year to 10 million by 2050. To effectively contain and mitigate AMR, we need more evidence of the drivers and impacts of AMR on human, animal and environmental health, and the links between them. We also need to turn evidence into action and tailored, sustainable approaches for countries and communities, which put clinicians and patients at the centre. Excellent research is underway across the world into innovation (including new treatments, diagnostics and vaccines), infection prevention and behavioural interventions. In this article, we explore how, where and why research should be intensified, with increased collaboration and transparency, to strengthen global health security and secure the future of modern medicine for patients globally.
随着耐药病原体在全球出现并传播，抗菌（尤其是抗生素）治疗的效果越来越差。由于人类和动物的感染变得更加复杂且治疗成本更高，抗菌药物耐药性（AMR）已成为一个规模和复杂性日益增加的全球性挑战。如果我们不长期采取行动并考虑可持续性，那么我们目前看到的全球每年70万例死亡人数到2050年将每年增至1000万。为了有效遏制和减轻抗菌药物耐药性，我们需要更多关于抗菌药物耐药性对人类、动物和环境健康的驱动因素及影响以及它们之间联系的证据。我们还需要将证据转化为行动，并为各国和社区制定量身定制的可持续方法，将临床医生和患者置于中心位置。世界各地正在开展关于创新（包括新治疗方法、诊断方法和疫苗）、感染预防和行为干预的出色研究。在本文中，我们探讨了应如何、在何处以及为何加强研究，通过加强合作与提高透明度，以加强全球卫生安全并为全球患者确保现代医学的未来。
